French Transparency Commission recognizes efficacy of Eisai’s Zonegran monotherapy
Transparency advice for Japanese pharma major Eisai’s (TYO: 4523) Zonegran (zonisamide) monotherapy in the treatment of partial seizures, with or without secondary generalization, in adults with newly-diagnosed epilepsy, has been published by the French National Authority for Health (HAS).
The Transparency Commission advice awards zonisamide a Medical Benefit (SMR) level of 'important' and an Improvement of Medical Benefit (ASMR) level 'V.’ The advice recognizes zonisamide's level A efficacy rating, Eisai noted.
Once-daily zonisamide is a second-generation anti-epileptic drug (AED) with multiple mechanisms of action and a chemical structure unrelated to any other AEDs. It is already available in France as adjunctive therapy in the treatment of partial seizures, with or without secondary generalization, in adults over the age of 18.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze